IL-ADTALEM
ACAMS, in partnership with artificial intelligence (AI) company ElephantThink, has successfully conceptualized and delivered its first fully online web-based compliance training program for Dutch banking group ING. The training partnership is for a multi-lingual SaaS solution offering mobile and web-based access to equip recipients with core competencies required to perform analysis, onboarding and anti-money laundering prevention roles and considered pioneering in the world of financial crime prevention training.
ING, which has a presence in over 40 countries serving over 38 million customers, places great emphasis on compliance, know your customer (KYC) / customer due diligence (CDD) and enhanced due diligence (EDD), which is reflected in the 4-year training agreement with ACAMS and ElephantThink.
Under the terms of the partnership, training is delivered digitally via e-learning on the ElephantThink Smart Learning Platform, and accessible in nine languages - English, Dutch, French, German, Italian, Romanian, Spanish, Turkish and Polish. Learners will have the ability to access the web-based learning curriculum supported by a companion mobile application which includes gamification elements to drive engagement and information retention. Qualifying ING employees will receive a verifiable digital certificate upon completion of their training.
Commenting on the training partnership, Roel Louwhoff, chief operations officer and chief transformation officer of ING, said: “As a gatekeeper to the financial system, ING has a responsibility to protect it, our customers and society against financial and economic crimes. Partnering with ACAMS to introduce their internationally recognized and certified digital training enables us to further enhance the KYC knowledge, skills and expertise of our employees in an innovative and engaging manner. This helps to fight financial economic crime, ensuring our customers can continue banking safely and securely as we empower them to stay a step ahead in life and in business.’’
Angela Salter, Interim President of ACAMS, said, “This is our first foray into delivering global web-based training to the KYC / CDD and transaction monitoring (TM) teams, and the promise of accelerated reach and efficacy is especially significant in the current environment. The commitment of ING to support a revolutionary training approach for a highly regulated and constantly evolving operating landscape cemented the success of our ground-breaking partnership with ElephantThink.”
Jack Smies, CEO of ElephantThink, said, “The mix of very high quality content from our partner ACAMS combined with our capabilities on AI, gamification and digital claims can really turbo charge people’s learning, which is reflected in the initial response and results of the training.”
Under the terms of the partnership ACAMS will make available AML, Sanctions, KYC and Transaction Monitoring programmes as well as ACAMS Certified Know Your Customer Associate (CKYCA) training at foundational and intermediate levels. These trainings are available in English, Dutch and multiple other languages, providing front-line and operations teams with the tools to perform KYC, CDD and EDD duties. ING’s sanctions, AML compliance and audit team learners will also have access to the full suite of ACAMS courses for the 2nd and 3rd lines of defence, underpinned by ACAMS’ comprehensive continuous education and alerts programme.
In a separate development, ACAMS has been granted approval by the Netherlands training registry body CRKBO to provide anti-financial crime training on a VAT free basis in the country, representing a savings of 21% on every ACAMS training course procured direct from ACAMS including its gold-standard CAMSTM Certified AML Specialist and recently launched Certified Global Sanctions Specialist (CGSS) qualifications.
About ACAMS®
ACAMS is a member of Adtalem Global Education (NYSE: ATGE), a leading workforce solutions provider headquartered in the United States. ACAMS is the largest international membership organization dedicated to enhancing the knowledge and skills of anti-money laundering (AML) and financial crime prevention professionals from a wide range of industries. Its CAMS certification is the most widely recognized AML certification among compliance professionals worldwide. Its new Certified Global Sanctions Specialist (CGSS) certification commenced in January 2020. Visit acams.org for more information.
About Adtalem Global Education
The purpose of Adtalem Global Education is to empower students to achieve their goals, find success, and make inspiring contributions to our global community. Adtalem Global Education Inc. (NYSE: ATGE; member S&P MidCap 400 Index) is a leading workforce solutions provider and the parent organization of American University of the Caribbean School of Medicine, Association of Certified Anti-Money Laundering Specialists, Becker Professional Education, Chamberlain University, EduPristine, OnCourse Learning, Ross University School of Medicine and Ross University School of Veterinary Medicine. For more information, please visit adtalem.com and follow us on Twitter (@adtalemglobal ) and LinkedIn .
About ElephantThink:
ElephantThink is an Artificial Intelligence company that focuses on algorithms and models. By applying this specifically to employee training and development they created a Smart Learning Platform. This smart learning platform can provide hyper personalization so that the learning is optimized for maximum efficiency per individual learner and is unique in that it adapts to the specific way each participant learns. By using spaced repetition of learning elements that are memory dependent, gamification to ensure user engagement and verifiable certificates and badges for user motivation and recognition ET is able to significantly improve the learner’s development. Visit elephantthink.com for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200816005023/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom